Top results
january 25 2019 icici securities ltd retail equity research result update well rounded growth beat on all fronts… biocon’s q3fy19 numbers were a comprehensive beat…
presented by :abhinandan mehrotra(04) akanksha arora(12) aman goel(18) amanpreet kaur(19) anukriti singh biocon industry: biotechnology founder: kiran mazumdar shaw founded…
slide 1 investor presentation april 2012 certain statements in this release concerning our future growth prospects are forward- looking statements, which are subject to a…
powerpoint presentation 1 fy14 results 2 certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a…
1. investor presentation october 2011 2. disclaimer certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject…
1. results presentation fy 2012 2. safe harbor certain statements in this release concerning our future growth prospects are forward- looking statements, which are subject…
1.bse code : 532523 nse code : biocon sector : pharmaceuticals report date : thu apr 24 06:46:59 edt 2014 industry overview market cap market cap is the price of all the…
8lcccn llml1lu anjana g¢vavia dhivva javavaman xiaovu liang lndla's loremosl 8lolech companv 8ackc8cunu 8locon was found ln november 29 lh 1978 locused from enzvmes…
biocon- case study presented by: krishna kanta mohd. azam imam nimish kapoor nitin tripathi paritosh tiwari biocon industry: biotechnology founder: kiran mazumdar…
submitted by:aparna vyas barun kumar jayshree bharti manoj dubey rajesh kumar saurabh mehta manoj dubey veeresh tripathi global biotechnology industry discovery of recombinant…
1. investor presentationseptember 2011 2. disclaimercertain statements in this release concerning our future growth prospects areforward-looking statements, which are subject…
1. investor presentationjanuary 2012 2. safe harborcertain statements in this release concerning our future growth prospects are forward-looking statements, which are subject…
1. investor presentationmarch 2012 2. safe harborcertain statements in this release concerning our future growth prospects are forward-looking statements, which are subject…
research journal of engineering sciences ___________________________________________ issn 2278 – 9472 vol. 2(6), 45-51, june (2013) res. j. engineering sci. international…
page | 1 biocon- making survival cheaper company overview and stock price 3 product overview 4 syngene: exclusively inclusive 6 pharma sector outlook 7 govt initiatives in…
7/28/2019 biocon vikash presentation 1/28biocon ltd: building a biotech powerhousefrom bottom to topby-manoj dubeykanishka pathakvikash thakurveer chhatarashalakhilesh kumarshadab…
krabeva leaflet.cdrdose reduction for adverse reactions is not recommended for bevacizumab. ÿ front-line treatment (in combination with carboplatin and paclitaxel) of
8/10/2019 biocon business ethics 1/21case study: bioconindiasown home-grown biotechcompany8/10/2019 biocon business ethics 2/21overview of biocon biocon, indias own home-…
biocon_final_ar21.cdrms kiran mazumdar-shaw, biologics limited and syngene international limited, is guided by the csr committees, constituted of members of the board of
ehs policy 2019-eng-kan.cdr